Barnadas, AMuñoz, MMargelí, MChacón, J ICassinello, JAntolin, SAdrover, ERamos, MCarrasco, EJimeno, M AOjeda, BGonzález, XGonzález, SConstenla, MFlorián, JMiguel, ALlombart, ALluch, ARuiz-Borrego, MColomer, RDel Barco, SGEICAM, Spanish Breast Cancer Group2025-01-072025-01-072019-12-21https://hdl.handle.net/10668/25668Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM. Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL. Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0-1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity. BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients. NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AssessmentsBone metastasisMetastatic breast cancerPsychometricQuality of lifeTreatmentresearch article31865481open access10.1186/s41687-019-0161-y2509-8020PMC6925605https://jpro.springeropen.com/track/pdf/10.1186/s41687-019-0161-yhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6925605/pdf